Furthermore, oncogenic activation of the AKT-mTOR signaling pathway promotes immune escape by driving the expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lung cancer where combination therapy of an mTOR inhibitor with a PD-1 antibody decreased tumor growth and increased T cell infiltration [33]. Here, MTOR is linked to lung cancer.